Storys zum Thema Krankheit
- Ein Dokumentmehr
- 3
canSERV Initiative: EU Consortium Launches Groundbreaking Call to Accelerate Cancer Research
Ein Dokumentmehr Press release: STADA continues with double-digit sales and profit growth in 2023
Ein DokumentmehrLeipzig Tourismus und Marketing GmbH
5Pioneering Heart Surgery and Medical Congresses in Leipzig
Ein DokumentmehrStrengthening the Direct Sales and Service System for Business Expansion in Italy
Ein DokumentmehrPress release: STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara - Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within ...
Ein Dokumentmehr- 3
EU Provides 1 Mio. to Researchers to Advance Personalised Oncology
Ein Dokumentmehr canSERV Releases Open Call for Transnational Service Provision
Ein Dokumentmehr- 2
Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals
Ein Dokumentmehr - 2
Press release: STADA's excellent results in H1 2023 indicate a record annual profit of €1 bn, driven by Consumer Healthcare and Specialty
Ein Dokumentmehr - 5
Press Release - hubergroup India expands its support for rural healthcare
Ein Dokumentmehr Free Access to Cancer Research Services - canSERV 1st Call for Proposals
Ein DokumentmehrInnovation and Start-up Center Biotechnology (IZB) welcomes Invitris
Ein DokumentmehrPress release: EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) - Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) ...
Ein DokumentmehrPress release: Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe
Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe - Launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrate-free adalimumab in Europe - Follows initial introduction of adalimumab in ninecountries: ...
Ein DokumentmehrPress release: STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®
STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis® - European Commission grants pan-EU marketing authorization for Ximluci® biosimilar referencing Lucentis® (ranibizumab) - Paves way for European ...
Ein DokumentmehrPress release: STADA sets standard in Specialty by launching the first medicine authorized in the EU for treating rare kidney disease
STADA sets standard in Specialty by launching the first medicine authorized in the EU for treating rare kidney disease - Germany is STADA’s lead launch market for EU’s first authorized treatment for a rare kidney disease immunoglobulin A ...
Ein DokumentmehrPress release: Strong in-market performance leads STADA to double-digit growth
Strong in-market performance leads STADA to double-digit growth - Continued strong organic market-share gains across key European markets, supported by several launches - Adjusted Group sales advance by 15% while adjusted EBITDA improve by 23% in first half of 2022 - STADA CEO Peter Goldschmidt: “In ...
Ein DokumentmehrPress release: STADA welcomes EU approval of Kinpeygo® for adults with primary IgA nephropathy
STADA welcomes EU approval of Kinpeygo® for adults with primary IgA nephropathy - The European Commission (EC) has granted conditional marketing authorization for Kinpeygo® for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a ...
Ein DokumentmehrPress release: STADA and Alvotech broaden European patients’ options by launching a high-concentration, citrate-free adalimumab
STADA and Alvotech broaden European patients’ options by launching a high-concentration, citrate-free adalimumab - Offers a comprehensive range of presentations to the EU adalimumab biosimilars market - Adalimumab marks the first molecule ...
Ein Dokumentmehr- 3
Sysmex Europe SE and Sysmex Inostics GmbH launch two CE-IVD certified Plasma-SeqSensei™ liquid biopsy kits: Solid Cancer IVD Kit and Breast Cancer IVD Kit
Ein Dokumentmehr Innovation and Start-Up Center for Biotechnology (IZB) welcomes new start-up Origin.Bio
Ein Dokumentmehr- 4
RTL Donation Marathon: Einhell offers support to children suffering from cancer
Ein Dokumentmehr - 2
The start-up Eisbach Bio in the IZB near Munich receives 6.7 million euros from the Bavarian state government for the development of a COVID-19 therapeutics
Ein Dokumentmehr - 2
COVID-19: Start-up Eisbach Bio at the IZB receives EUR 8 million government grant
Ein Dokumentmehr - 7
Biotech start-ups at the IZB close deals worth more than 140 million EUR in the first half of 2021
Ein Dokumentmehr - 2
Lindis Biotech develops immunotherapy against bladder cancer
Ein Dokumentmehr Origenis founds biotech company Neuron23 in Silicon Valley together with star investor Kleiner Perkins
Ein Dokumentmehr- 2
A higher omega-3 level apparently protects from dying from COVID-19
Ein Dokumentmehr - 3
World Cancer Day: Start-ups at the IZB develop innovative cancer drugs and diagnostic tools
Ein Dokumentmehr